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MitophagyThe p53 tumor suppressor plays a central role indictating cell survival anddeath as a cellular sensor for amyriad of
stresses includingDNAdamage, oxidative and nutritional stress, ischemia and disruption of nucleolar function. Ac-
tivation of p53-dependent apoptosis leads tomitochondrial apoptotic changes via the intrinsic and extrinsic path-
ways triggering cell death execution most notably by release of cytochrome c and activation of the caspase
cascade. Although it was previously believed that p53 induces apoptotic mitochondrial changes exclusively
through transcription-dependentmechanisms, recent studies suggest that p53 also regulates apoptosis via a tran-
scription-independent action at themitochondria. Recent evidence further suggests that p53 can regulate necrotic
cell death and autophagic activity includingmitophagy. An increasing number of cytosolic andmitochondrial pro-
teins involved inmitochondrial metabolism and respiration are regulated by p53, which inﬂuencesmitochondrial
ROS production as well. Cellular redox homeostasis is also directly regulated by p53 throughmodiﬁed expression
of pro- and anti-oxidant proteins. Proper regulation ofmitochondrial size and shape through ﬁssion and fusion as-
sures optimalmitochondrial bioenergetic functionwhile enabling adequatemitochondrial transport to accommo-
date local energy demands unique to neuronal architecture. Abnormal regulation of mitochondrial dynamics has
been increasingly implicated in neurodegeneration,where elevated levels of p53may have a direct contribution as
the expression of some ﬁssion/fusion proteins are directly regulated by p53. Thus, p53may have amuchwider in-
ﬂuence on mitochondrial integrity and function than one would expect from its well-established ability to tran-
scriptionally induce mitochondrial apoptosis. However, much of the evidence demonstrating that p53 can
inﬂuence mitochondria through nuclear, cytosolic or intra-mitochondrial sites of action has yet to be conﬁrmed
in neurons. Nonetheless, as mitochondria are essential for supporting normal neuronal functions and in initiat-
ing/propagating cell death signaling, it appears certain that the mitochondria-related functions of p53 will have
broader implications than previously thought in acute and progressive neurological conditions, providing new
therapeutic targets for treatment. This article is part of a Special Issue entitled: Misfolded Proteins, Mitochondrial
Dysfunction, and Neurodegenerative Diseases.
Published by Elsevier B.V.1. Introduction
p53 is a transcription factor that activates or represses the expression
of multiple genes [1], but it is also found in the cytosol and mitochondria
eliciting an increasing repertoire of extra-nuclear, non-transcriptional
functions. p53 expression is upregulated in response to a diverse array
of cellular stresses, including DNA damage, hypoxia, oxidative and nutri-
tional stress, ribonucleotide depletion, disruption of nucleolar function
and oncogene activation [2,3]. p53 regulates DNA repair, metabolism,
cell cycle progression, senescence and apoptosis, thus playing a key role
in tumor suppression, aging and neurodegeneration [4–7]. These multi-
faceted p53 functions are realized via a surprisingly large number of
p53-regulated proteins and pathways with a signiﬁcant fraction of them
converging on the mitochondria. This review is focused upon p53olded Proteins, Mitochondrial
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.functions that directly or indirectly regulate mitochondrial physiology
and its immediate up- and down-stream events (Fig. 1) and provides cur-
rent, still very limited assessment of those functions in neurons.
2. p53-mediated apoptosis (Fig. 2A)
Numerous studies have established that p53 promotes apoptosis by
transcriptionally activating or repressing the expression of a panel of
pro- and anti-apoptotic proteins. For apoptotic processes involving mito-
chondria, p53 transcriptionally activates Fas/Fas ligand and DR5/KILLER
for the extrinsic apoptotic pathway. For the intrinsic pathwayp53 induces
expression of PUMA, Noxa, Bid, Bad, p53AIP1, Bax and APAF1 among
others [1,8,9], maintains basal expression of apoptosis-inducing factor
(AIF) [10], and represses expression of Bcl-2 [11], Bcl-xL [12] and Mcl-1
[13], consequently triggering release of apoptogenic proteins including
cytochrome c and AIF from the mitochondrial intermembrane space.
These pathways contribute to neuronal cell death and neurodegeneration
but the critical playersmediating the pathwaymay vary depending upon
the nature of the apoptotic stimulus [14–18].
Fig. 1.p53 plays numerous distinct roles inmitochondria-related processes, such as apoptosis/necrosis, autophagy/mitophagy,mitochondrial quality control and cellular redox regulation,
depending on its expression levels, subcellular localization, availability of cell-speciﬁc binding partners, and cellular state (i.e. resting versus stressed). Nuclear p53 is activated (upregu-
lated and/or stabilized) by cellular stress including DNA damage, hypoxia, oxidative stress (ROS), nucleolar stress and starvation, and transcriptionally activates or represses p53 target
genes, leading to a variety of downstream effects. p53 can also translocate to the cytoplasm and tomitochondria, where it can directly bind to and activate or inhibit proteins andpathways
related to mitochondrial function. p53 actions related to mitochondrial quality control (to the left) are largely functional at basal (physiological) levels of p53 expression, while its
pro-death function (to the right) requires higher levels of p53. The same is generally true at the individual gene/protein level within any speciﬁc category of p53 function where
pro-survival actions are seen with physiological levels of p53 expression, while pro-death actions are induced by upregulated levels of p53.
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non-transcriptional inducer of apoptosis, which involves its direct
action at the mitochondria [19,20]. In this model, a cytoplasmic pool of
p53 rapidly translocates to the surface of the outer mitochondrial mem-
brane in response to stress, where it behaves like a BH3-only protein
physically interacting with anti-apoptotic (Bcl-xL, Bcl-2, Mcl-1) and/or
pro-apoptotic (PUMA, Bax, Bak)members of the Bcl-2 family. These inter-
actions eventually facilitate Bax/Bak-mediated permeabilization of the
outer mitochondrial membrane leading to release of cytochrome c and
the activation of the caspase cascade. Consistent with p53 acting directly
atmitochondria, p53proteinhas been localized inmitochondrial fractions
after stress [21–23] and directly targeting p53 to the mitochondrial outer
membrane is sufﬁcient to promote apoptosis in the absence of any
external stress [21,24]. While the evidence for a direct action of p53 at
themitochondria is compelling, it was derived from studies using normal
and tumor cells of non-neuronal origin.
Evidence for a directmitochondrial action of p53 in neurons is not as
abundant and remains inconclusive. Although initial studies appeared
to have established that p53 immunoreactivity is conﬁned to the nucle-
us in neurons destined to die [15,25–27], in agreementwith nuclear p53
function being essential for apoptosis induction, there have been several
reports describing cytoplasmic accumulation of p53 in neurons, but
with no demonstration that this had functional consequences for viabil-
ity [28–30]. Subsequent to the demonstration of extra-nuclear apoptotic
activity of p53 in non-neuronal cells, several studies have since demon-
strated a potential role formitochondrial p53 inmediating neuronal ap-
optosis using various in vitro and in vivo models [31–37]. However,
none of these studies has provided deﬁnitive proof for a mitochondrial
site of p53 action in neurons. Deﬁnitive evidence in support of a mito-
chondrial site of action for p53 would include its physical association
with mitochondria and its molecular interaction with either members
of the Bcl-2 family of proteins or other intrinsic mitochondrial proteins.
The evidence available from these studies is still not conclusive in that a
mitochondrial association for p53 has principally been demonstrated by
immunoﬂuorescence colocalization. When data is presented in supportof p53's physical association with mitochondria and/or its molecular
interaction with an appropriate protein in mitochondrial fractions, the
results cannot be strictly associated with neurons because the analysis
has been done using whole brain tissue. In this regard, Endo et al. [31]
used micro-dissected CA1 pyramidal cell layer tissue to demonstrate a
p53-Bcl-xL interaction in mitochondrial fractions and, therefore, the
result is more likely to represent a neuronal event. A functional contri-
bution of mitochondrial p53 to apoptosis has been demonstrated by
using piﬁthrin compounds. Piﬁthrin-α [38] and piﬁthrin-μ [39] speciﬁ-
cally inhibit the nuclear (transcriptional) and mitochondrial (non-
transcriptional) actions of p53, respectively, although their speciﬁcities
have not been critically tested in neurons. The results obtained with
these inhibitors are not consistent and suggest context-dependent,
variably proportionate contributions of nuclear and mitochondrial p53
to neuronal apoptosis [31,32,35–37]. A shift in sensitivity from
piﬁthrin-α to piﬁthrin-μ is also observed as neurons mature in culture
[34]. Collectively, these studies appear to suggest that mitochondrial
p53 action contributes to neuronal apoptosis but to a variable extent.
Results from some of these studies [31,32,36], however, suggest that
the action of piﬁthrin-α and piﬁthrin-μmay not be exclusively conﬁned
to their expected sites of action, nucleus andmitochondria, respectively,
although some “non-speciﬁc” effects of piﬁthrin-μ on nuclear p53 activ-
ity may be explained by a potential increase in nuclear p53 concentra-
tion when p53 translocation to mitochondria is blocked by piﬁthrin-μ.
Piﬁthrin-α has been widely used to inhibit the nuclear, transcriptional
activity of p53, but it may possess some nonspeciﬁc actions [40–42].
Cautionmust be takenwhen assessingmitochondrial p53 function sole-
ly on the basis of the sensitivity to piﬁthrin-μ because the speciﬁcity of
this compoundhas recently been challenged. Leu et al. [43] demonstrate
that the direct target of piﬁthrin-μ action is actually heat shock 70 kDa
protein (HSP70). Piﬁthrin-μ disrupts the association between HSP70
and its cofactors and client proteins, the latter of which include p53,
APAF1 and autophagy-related proteins (p62, LAMP2). This results in
compromised activation of both the caspase cascade and autophagy as
well as reduced localization of p53 to mitochondria. Also, piﬁthrin-μ
Fig. 2. p53-Regulated proteins and their interacting proteins and pathways in relation to mitochondrial function. Note that p53-mediated regulation of gene expression is most likely cell
and stress type-speciﬁc and the proteins listed as “induced/repressed by p53”maynot be regulated thatway in neurons. Proteins are listed as “transcriptionally induced/repressed by p53”
only when the transcriptional regulation has been demonstrated at the gene structure level (promoter reporter assay, CHIP analysis). Not all proteins/genes mentioned in the text are
presented in these ﬁgures. Promotive (red arrow) and suppressive (blue line with stop) actions represent the intrinsic action of the corresponding molecules. Note that essentially all
the apoptosis-related proteins shown in (A) are transcriptionally regulated in similar ways in neurons at least under certain speciﬁc apoptotic conditions, but this is not reﬂected in
the ﬁgure for the purpose of simplicity. Abbreviations: AIF: apoptosis-inducing factor, mitochondrion-associated, 1; ALDH4; aldehyde dehydrogenase 4 family, member A1: AMPK: 5′
adenosine monophosphate-activated protein kinase; APAF1: Apoptotic peptidase activating factor 1; Bad: Bcl-2-associated death promoter; Bak: Bcl-2-homologous antagonist/killer;
Bax: Bcl-2-associated X protein; Bcl-2: B-cell lymphoma 2; Bcl-xL: B-cell lymphoma-extra-large (BCL2-like 1); Bid/tBid: (truncated) BH3 interacting domain death agonist; BNIP3:
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; COX: cytochrome c oxidase; CypD: cyclophilin D; CytC: cytochrome c; dNTPs: deoxyribonucleotide triphosphates; DR5:
tumor necrosis factor receptor superfamily, member 10b; DRAM: DNA damage-regulated autophagy modulator protein; Drp1: dynamin-related protein 1; Ei24: etoposide-induced pro-
tein 2.4 homolog (PIG8); ER: endoplasmic reticulum; FAS: Fas cell surface death receptor; FASL: FAS ligand; FR: ferredoxin reductase; G6PDH: glucose-6-phosphate dehydrogenase; GLS2:
phosphate-activated mitochondrial glutaminase; GPX1: glutathione peroxidase 1; GSH: reduced glutathione; LC3: microtubule-associated protein light chain 3; MALM: Mieap-induced
accumulation of lysosome-like organelles within mitochondria; Mcl-1: myeloid cell leukemia-1; Mfn2: mitofusin 2; Mieap: mitochondria eating protein; MIV: Mieap-induced vacuole;
MnSOD: manganese superoxide dismutase; MPTP: mitochondrial permeability transition pore; mtSSB; mitochondrial single-stranded DNA-binding protein: mtDNA: mitochondrial
DNA; Nix: NIP-like protein X (a.k.a., BNIP3-like protein); Noxa: phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1); NQO1: quinone oxidoreductase or NAD(P)H dehydroge-
nase, quinone 1; p53: tumor protein 53; p53AIP1: tumor protein p53 regulated apoptosis inducing protein 1; p53R2: ribonucleotide reductase M2 B (RRM2B); p66Shc: p66 isoform of
Src homology 2 domain-containing-transforming protein C1; PARP1: poly(ADP-ribose) polymerase 1; Pdk2: pyruvate dehydrogenase kinase isoform 2; PGC-1α: peroxisome
proliferator-activated receptor gamma coactivator 1-alpha; POX: proline oxidase 1; PPP: pentose phosphate pathway; Polγ: DNA polymerase subunit gamma; PTEN: phosphatase and
tensin homolog; PUMA: p53 upregulatedmodulator of apoptosis; ROS: reactive oxygen species; SCO2: cytochrome c oxidase assembly; SIRT1: sirtuin 1; TSC2: tuberous sclerosis protein
2; TFAM: mitochondrial transcription factor A; TIGAR: TP53-inducible glycolysis and apoptosis regulator; TP53AIP1: tumor protein p53 regulated apoptosis inducing protein 1; p53INP1:
VDAC: voltage-dependent anion channel.
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its multi-faceted action is not exclusively restricted to the inhibition of
mitochondrial p53 action.
We evaluated postnatal mouse cortical neurons in culture to deter-
mine if there was evidence for a signiﬁcant apoptogenic contribution of
the cytosolic/mitochondrial p53 pathway, but the results instead corrob-
orated the sole requirement for the transcriptional activity of p53 [17].The p53 protein did not accumulate at detectable levels in the mitochon-
dria during p53- and Bax-dependent apoptosis caused by camptothecin
(CPT; induces DNA strand breaks via topoisomerase I inhibition) or
nutlin-3 (upregulates p53 by inhibiting Mdm2-mediated degradation).
Expression of a dominant-negative p53 mutant, p53R273H, nearly
completely rescued neurons from these forms of apoptosis while sup-
pressing the induction of p53 target genes, PUMA and Fas, a ﬁnding that
1189D.B. Wang et al. / Biochimica et Biophysica Acta 1842 (2014) 1186–1197rules out the presence of apoptogenic mitochondrial p53 action since
p53R273H possesses little dominant-negative activity against mitochon-
drial wild-type p53 action [44]. In addition, exogenously-expressed p53
lost its apoptotic activity when directly targeted to the mitochondrial
outer membrane in neurons but not in non-neuronal cells [17].
The uniqueness of p53-mediated apoptotic signaling in postnatal
cortical neurons was further illustrated by the distinct function the
proline-rich (PP) domain of p53 plays in neurons and non-neuronal
cells [17]. In non-neuronal cells, the PP domain of p53 is required for
its overall apoptosis-inducing activity [45–47] and speciﬁcally for the
transcription-independent “BH3-only protein-like” death-promoting
action of p53 in the mitochondria as well [48,49]. In contrast, when
expressed in p53-deﬁcient neurons, a deletion mutant lacking the PP
domain (amino acids 62–91: p53ΔPP) exhibited the same degree of
apoptotic activity as wild-type p53 even in the absence of DNA damage
[17]. The naturally occurring polymorphism at codon 72 of human p53
(Pro vs. Arg) occurs in this PP domain, affecting nuclear export of p53 in
favor of p53Arg72 and, consequently, p53Arg72 exhibits greater
mitochondrial translocation and transcription-independent apoptotic
activity than p53Pro72 [23]. In mouse postnatal cortical neurons,
however, both human p53Pro72 and p53Arg72 showed exclusive nu-
clear localization and indistinguishable apoptotic activity [17]. Thus,
our results point to the possibility that the cellular context in postnatal
cortical neurons recognizes the p53molecule andmediates its apoptotic
activity differently compared to non-neuronal cells and, consequently,
is not conducive to p53 promoting apoptosis through themitochondria.
Cellular contexts may vary, however, even among neurons depending
upon the neuronal population being examined, the age of neurons
(embryonic, postnatal, adult), culture conditions, in vitro vs. in vivo, the
type of apoptotic stress employed, etc. Indeed, when expressed in rat
embryonic cortical neurons, p53Arg72, but not p53Pro72, accumulates
in the cytosol and activates the intrinsic apoptotic pathway, increasing
vulnerability to excitotoxic and ischemic apoptotic death [36].
The occurrence and signiﬁcance of p53 acting directly at the mito-
chondria in neurons remain to be further explored. The data accumulat-
ed thus far suggest that a mitochondrial site of p53 action in neurons
may occur under certain conditions, but biochemical analyses using
whole brain tissue and functional analyses based on piﬁthrin sensitivity
make it difﬁcult to draw a ﬁrm conclusion at this point. Neurons may
utilize the transcription-independent mitochondrial p53 pathway to a
variable extent depending on parameters not fully understood.
3. p53 regulates necrosis and autophagy (Fig. 2A, C)
The cell fate-determining action of p53 on mitochondria may not be
restricted solely to the activation of apoptotic cell death. p53 has recent-
ly been suggested to regulate programmed necrotic death, an irrevers-
ible form of cell destruction that results from an acute failure in
energy production due to the opening of the mitochondrial permeabil-
ity transition pore (MPTP). Oxidative stress has been shown to stabilize
and promote p53 accumulation in the mitochondrial matrix [50,51]. A
recent study demonstrates that, in response to oxidative stress, p53
localized in the mitochondrial matrix can promote the opening of the
MPTP via its direct interaction with the MPTP regulator, cyclophilin D
[51]. A complex between p53 and cyclophilin D is also detected in ne-
crotic brain tissue in a model of transient ischemic stroke. Intriguingly,
amore prominent reduction in infarct sizewas observed inmice lacking
one p53 allele (p53+/−) than in p53-null (p53−/−) mice, which is, in
fact, consistent with a previous observation [52] but requires further
clariﬁcation for the underlying molecular mechanism. This ﬁnding is
provocative as it ties p53 to necrotic cell death in the brain for the ﬁrst
time, but it remains to be demonstrated if this necrotic mode of mito-
chondrial p53 action indeed occurs in neurons and if it is associated
with the loss of neurons only in the ischemic core (necrotic) or in the
penumbra (apoptotic) as well. An interaction between p53 and the
voltage-dependent anion channel (VDAC), another key structuralcomponent of the mitochondrial permeability transition pore, was
also found by co-immunoprecipitation in PC12 cells and, interestingly,
the interaction was attenuated upon etoposide treatment [53]. p53-
Mediated formation of large VDAC-containing protein complexes has
also been reported [51]. Thus, p53 may interact with VDAC under
normal conditions and then shift the interaction toward cyclophilin D
under conditions that precipitate necrosis. A more recent study demon-
strates another mode of p53-dependent “non-apoptotic” cell death in
mouse embryonic ﬁbroblasts (MEFs) and human tumor cell lines [54].
This mode of cell death is induced by H2O2 at a concentration that
exceeds the levels that trigger the p53-cyclophilin D interaction men-
tioned above [51] and occurs in wild-type and even Bax/Bak double
knockout MEFs but not in p53−/− MEFs, thus making it p53-
dependent and Bax/Bak-independent (or non-apoptotic, necrotic) cell
death. DNA damage is involved with the resulting activation of
poly(ADP-ribose) polymerase 1 (PARP-1) and p53 deﬁciency causes a
decrease in PARP-1 activity consistent with the observation that inhibi-
tion of PARP-1 activity is protective. This p53-dependent, PARP-1-
mediated non-apoptotic (or necrotic) cell death is not inhibited by
cyclosporine A, an MPTP inhibitor, and is largely unchanged in
cyclophilin D knockout cells and, therefore, is unlikely to be mediated
by the opening of the PTP [54].
An increasing number of proteins involved in autophagy are now
known to be regulated by p53. Autophagy is pro-survival, for example,
under conditions of mild nutritional stress, while dysregulated and
excessive autophagy can precipitate cell death. Autophagic activity is
also critical for the execution of mitophagy, a selective form of autoph-
agy responsible for the degradation of damaged mitochondria. Under
conditions of stress, p53 can promote autophagy via the transcriptional
activation of autophagic genes such as TSC2 (tuberous sclerosis 2), the
beta 1 and beta 2 subunits of AMPK, sestrin 1 and 2, and PTEN [55].
Additionally, p53 can promote autophagy by facilitating the release of
the autophagic protein beclin 1 from sequestration by Bcl-2, Bcl-xL
and Mcl-1 by repressing transcription of these sequestering proteins
(Bcl-2, Bcl-xL and Mcl-1) [11–13], or by increasing expression of Bax,
Bad and PUMA [56,57]. Tumor protein p53 inducible nuclear protein 1
(TP53INP1), originally identiﬁed as a p53 target gene and designated
as p53DINP1, encodes a nuclear protein that works to further enhance
p53 function [58]. Upon induction of autophagy this protein translo-
cates to autophagosomes and purportedly promotes autophagy by
binding to LC3 to displace p62. TP53INP1 overexpression can induce
caspase-dependent autophagic cell death [59]. TP53INP1 mRNA is
upregulated in response to copper-induced apoptosis in NTERA-2-N
neurons, but its autophagic contribution to cell death has not been
demonstrated [60]. p53 also activates the autophagy pathway by
transcriptionally upregulating a lysosomal protein, damage-regulated
autophagy modulator (DRAM), which causes little cell death by itself
when overexpressed, but is required for p53-mediated cell death [61].
DRAM is expressed in multiple spliced forms and their additional local-
ization at multiple sites other than lysosomes is indispensable for the
whole range of DRAM functions [62]. p53-Mediated induction of
DRAM has been reported in a rat model of Huntington's disease where
striatal neuron death is induced by striatal administration of a mito-
chondrial complex II inhibitor, 3-nitropropionic acid. Induction of
DRAM together with LC3 upregulation is blocked by piﬁthrin-α admin-
istration and striatal neuron death is strongly attenuated by autophagy
inhibitors [63]. A similar relationship between p53-mediated induction
of DRAM and autophagic activity is observed when excitotoxic death of
striatal neurons is induced by quinolinic acid [64]. In kainic acid-
induced excitotoxic cell death in striatal neurons in vitro, autophagic
proteins and activity are induced in a p53-dependent manner based
on their sensitivity to piﬁthrin-α and, to a lesser extent, piﬁthrin-μ [37].
Conversely, in contrast to the transcriptional activation of autophagy
by nuclear p53 under conditions of stress as described above, cytoplas-
mic p53 can suppress autophagy [65]. Deletion, depletion or inhibition
of p53 in a variety of normal and transformed human cell lines is
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(starvation, rapamycin and ER stress) enhance p53 degradation.
Restoring cytoplasmic, but not nuclear, p53 in p53-deﬁcient HCT116
human colon carcinoma cells can inhibit autophagy induction [65].
Transcription-independent effects of p53 on the AMPK/mTOR axis, a
key pathway for autophagy regulation, is suspected of mediating the
autophagy-suppressing action of cytoplasmic p53 [65], but p53-
mediated post-transcriptional downregulation of LC3 protein as dem-
onstrated in the same HCT116 cells in response to prolonged starvation
[66] may also have some mechanistic implication in this cytoplasmic
p53 action. The autophagy-suppressing action of cytoplasmic p53 has
not yet been demonstrated for neurons.
A p53-regulated increase in autophagic activity may be broadly
associated with different forms of neuronal cell death, but its overall
contribution to the demise of neurons requires further clariﬁcation
since autophagy can be protective when stress levels are sub-lethal or
when autophagy is activated early on in the process of cell death. For
example, nucleolar stress-induced p53 in striatal neurons in a model
of Huntington's disease transiently upregulates PTEN and the resulting
induction of autophagy exerts a neuroprotective effect [67]. Since both
impaired autophagy and excessive activation of autophagy can be path-
ogenic in nervous system injury and neurodegenerative diseases [68],
autophagy-related actions of p53 may also variably affect viability in
neurons. The autophagy-modulating action of p53 is also relevant to
mitochondrial quality control through autophagic clearance of damaged
mitochondria (see below).
4. p53 and mitochondrial quality control
Maintaining a pool of viable mitochondria is essential for sustaining
normal cellular function, especially for neurons, a cell type with high
energy demands that can only be met through the process of oxidative
phosphorylation. The quality of mitochondrial function is assured “struc-
turally” by the production of healthy mitochondria (mitochondrial bio-
genesis) and removal of non-functional mitochondria (mitophagy) and
“functionally” by the health of the systems involved in metabolism
(glycolysis, TCA cycle, oxidative phosphorylation) and the associated
production of reactive oxygen species (ROS), a critical component that
determines cellular redox homeostasis that is kept in balance with the
anti-oxidant system. Recent studies have revealed a signiﬁcant contribu-
tion of p53 to each of these aspects of mitochondrial function as detailed
below.
4.1. p53 and mitophagy (Fig. 2C)
Mitophagy is a selective form of autophagy by which damaged
mitochondria are eliminated in autolysosomes [69]. Damaged or non-
functional mitochondria produce excess ROS, potentially activating
cell death signaling and, therefore, their timely removal is critical in
maintaining the cellular redox homeostasis. When this degradative
process becomes dysregulated and excessive, however, mitophagy
may be detrimental, culminating in a bioenergetic crisis. Mitophagy is
regulated by an increasing number of proteins that reside in the mito-
chondria or become associated with mitochondria when required,
such as PINK1, parkin, BNIP3, NIX and FUNDC1 [69–71]. The expression
and function of some of these proteins is regulated by p53.
The PINK1/parkin pathway plays a major role in mitochondrial
quality control by marking damaged (loss of membrane potential)
mitochondria for mitophagy [69–71], although this remains to be
established for neurons [72]. Parkin, a gene associated with early
onset forms of Parkinson's disease, was recently identiﬁed as a p53 tar-
get gene, increasing its expression upon p53 upregulation both in
human and mouse cells [73]. In contrast, we found that p53 suppresses
parkin protein expression in postnatal mouse cortical neurons with lit-
tle suppression at themRNA level [74], suggesting that p53 can regulate
parkin expression both transcriptionally and post-transcriptionally anddistinctly between non-neuronal cells and at least some neuronal
populations. Interestingly, parkin reciprocally acts on the p53 gene as
a transcriptional repressor by binding to the p53 promoter region [75].
Parkin overexpression suppresses p53 expression and apoptosis (cas-
pase-3 activity) in 6-hydroxydopamine-treated ﬁbroblasts, neuronal
cell lines and primary neurons [75]. Elevated levels of p53 expression
are observed in ﬁbroblasts and brain from parkin knockout mice and
in human brain afﬂicted by autosomal recessive juvenile parkinsonism
caused by parkin mutations, which abolish the protective action of
wild-type parkin [75]. Consistent with this ﬁnding, a recent report
suggests that modiﬁcation of parkin by S-nitrosylation abolishes the
ability of parkin to suppress p53 expression and the levels of both
S-nitrosylated parkin and p53 are simultaneously elevated in
Parkinson's disease brain [76].
The interaction between p53 and parkin can also occur through a
direct protein–protein interaction. The main function of parkin in mito-
chondrial quality control is its ability to mark damaged mitochondria
for mitophagy through its ubiquitin ligase activity. In a model of
doxorubicin-induced cardiotoxicity and aging-associated heart failure
in mice cytosolic p53 directly binds to parkin, blocking its translocation
to damaged mitochondria and thereby their subsequent clearance by
mitophagy [77]. The signiﬁcance of this p53-parkin interaction in
neurons remains to be determined as it is highly dependent on cytosolic
expression of p53. In ischemic cardiac tissue,mitophagy is also impaired
due to p53-dependent transcriptional upregulation of TIGAR [77],
which suppresses autophagy through its ability to counteractmitochon-
drial ROS production via enhanced regeneration of NADPH and, conse-
quently, reduced glutathione (GSH) [78]. In p53−/− myocardium,
therefore, elevated ROS production is followed by homodimerization
and activation of BNIP3, an initiator of mitophagy (see below), that
serves as a basis for the observed cardioprotection [77].
BNIP3 (Bcl2 and adenovirus E1B 19 kDa-interacting protein 3) and
its homolog NIX (NIP-like protein X; a.k.a., BNIP3-like protein or
BNIP3L) are BH3 domain-only proteins residing in or translocating
upon activation to the outer mitochondrial membrane. However, they
exhibit relatively low apoptotic activity [79] and can additionally induce
caspase-independent permeability transition-mediated cell death and
autophagy/mitophagy [80]. They promote mitophagy by interacting
with LC3, a protein critical for autophagosome formation [71,80].
While BNIP3 and NIX are inducible transcriptional targets of HIF-1α,
they are also transcriptionally regulated by p53, but in different direc-
tions in response to hypoxic conditions in non-neuronal cells such
that BNIP3 is downregulated [81] while NIX is upregulated by p53
[82]. Although these regulatory pathways have not yet been established
for neurons, both BNIP3 [83–85] and NIX [86,87] are upregulated in
neurons in response to stress, suggesting that BNIP3 expression may
be regulated differently in neurons. In studies with neurons, however,
mitigating the upregulation of BNIP3 induced by oxidative and ischemic
stress is neuroprotective, suggesting that BNIP3/NIX-dependent
mitophagy may be excessive and detrimental or that BNIP/NIX work
as pro-death proteins.
Recent studies have implicated BNIP3 and NIX in a different form of
mitochondrial quality control that involves Mieap (mitochondria-eating
protein; a.k.a, spermatogenesis-associated protein 18 or SPATA18), a
p53-inducible gene that encodes a novel protein found in the mitochon-
drial matrix [88,89]. In response to stress, such as DNA damage, Mieap
is induced and translocates to the mitochondrial matrix in a ROS-
dependent manner [89], allowing lysosomal enzymes to move into the
matrix thereby facilitatingdegradationof oxidatively damagedmitochon-
drial proteins (designated MALM for Mieap-induced accumulation of
lysosome-like organelles within mitochondria [88]). This occurs only
when BNIP3 and NIX coexist at the mitochondrial surface [90]. The inter-
action between Mieap, BNIP3 and NIX appears to facilitate the formation
of a mitochondrial membrane pore involving both mitochondrial mem-
branes, thus causing a drop in membrane potential. However, the drop
in membrane potential is not sensitive to cyclosporine A, suggesting
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not the traditional mitochondrial permeability transition pore and, in-
deed, it does not lead to cell death in this model [90]. When the Mieap
pathway is activated, 14-3-3γ also translocates from the cytosol to the
mitochondrial matrix, where it interacts with Mieap and is required for
Mieap-promoted degradation of oxidized proteins by lysosomal enzymes
[91]. Interestingly, 14-3-3γ expression is suppressed byp53 [92], suggest-
ing that p53 can also curtail this pathway.When NIX is not available (not
yet known for BNIP3), cytosolic Mieap contributes to the formation of a
vacuole-like structure called MIV (Mieap-induced vacuole). The MIV en-
gulfs damaged mitochondria and fuses with lysosomes to promote the
elimination of unhealthy mitochondria, acting as a form of mitophagy
[89]. Thus,Mieap regulates the repair (withinmitochondria) and elimina-
tion (in cytosol) of oxidatively damaged mitochondria. Since all of these
proteins (Mieap, BNIP3, NIX, 14-3-3γ) are regulated in some manner by
p53, this pathwaymay prove to be very important in p53-mediatedmito-
chondrial quality control although its regulation is likely complex. High
levels of p53 expression can precipitate the opening of a cyclosporine
A-sensitive mitochondrial permeability transition pore associated with
necrosis [51,90]. In contrast, this Mieap-mediated mitochondrial quality
control pathwaymay be implicated in a cytoprotective response to stress
that is associated with more modest activation of p53, as observed under
chronic moderate oxidative stress. Mieap indeedmaintains normal mito-
chondrial function by suppressing ROS generation and promoting ATP
production under irradiation-induced oxidative stress [88]. The expres-
sion and function of Mieap in neurons have not yet been described.
The DNA damage response gene Ei24 (etoposide-induced 2.4 kb
transcript, also known as p53-induced gene 8 or PIG8) is a p53-
inducible gene [93] associated with the regulation of autophagy. Mice
displaying a neural-speciﬁc knockout of this gene demonstrate defects
in basal autophagy in oligodendrocytes and neurons and develop
age-dependent neurological abnormalities characterized by signiﬁcant
axonal demyelination and degeneration as well as extensive neuron
loss in the brain and spinal cord [94]. Thus, although its inducibility by
p53 in neurons has not yet been determined, p53-mediated Ei24
expression may sustain the basal rate of autophagic ﬂux in neurons,
playing an important role in the clearance of aggregate-prone proteins
[94]. Ei24 is known to be localized to the endoplasmic reticulum and
to bind to Bcl-2 in cancer cells [95]. A proteomic analysis [96] further
supports the association of Ei24 with, among others, the ATP synthase
complex and prohibitin, a mitochondrial inner membrane protein that
affects the processing of the inner membrane fusion protein OPA1
[97], suggesting that Ei24 may function directly in mitochondria. Its
mechanism of action and possible pro-survival function together with
its relationship to mitochondrial structure and function in neurons re-
quires further exploration.
4.2. p53 and mitochondrial biogenesis (Fig. 2C)
The production andmaintenance of functional mitochondria consti-
tutes another aspect of mitochondrial quality control. Maintenance of
mitochondrial DNA (mtDNA) integrity and copy number is fundamen-
tal to sustaining mitochondrial function. Accumulating evidence indi-
cates that p53 works as a guardian of the genome for mitochondria as
well. Among those proteins directly involved in this function within
mitochondria, nuclear DNA-encoded mitochondrial transcription factor
A (TFAM), essential for mtDNA replication, repair and transcription, is
the only protein thus far identiﬁed to be transcriptionally regulated by
p53 [98]. However, TFAM expression is p53-dependent in ﬁbroblasts
and muscle tissue, but not in the liver or heart, indicating cell type
speciﬁc inducibility [98]. Having been identiﬁed in the mitochondrial
matrix, p53 also protects the mitochondrial genome through direct in-
teractions with repair enzymes. p53 interacts with mitochondrial
single-stranded DNA-binding protein (mtSSB) [99] and TFAM [100]
forming p53/TFAM/mtDNA complexes [98,101,102] and also interacts
with mitochondrial DNA polymerase (Polγ) [103], thereby promotingreplication and base excision repair of mtDNA [103,104]. Consequently,
mtDNA copy number and mitochondrial mass are greater in p53-
expressing cells relative to p53-deﬁcient counterparts under various
conditions [98,103,105,106]. Also observed in p53-deﬁcient cells is
reduced expression of p53R2 [105,106], one of the two small subunits
(R2 and p53R2) comprising ribonucleotide reductase that supplies
dNTPs for DNA replication and repair. p53R2 (RRM2B gene) is transcrip-
tionally induced by p53 upon DNA damage and, unlike the R2 subunit,
translocates to the nucleus, where it is thought to constitute ribonucle-
otide reductase activity and supply dNTPs locally for DNA repair [107].
Although it is not known if p53R2 also resides in mitochondria, p53R2
is required for mtDNA synthesis in quiescent cells [108]. Consistently,
mtDNA depletion is seen in muscle from human patients with p53R2
mutations and in the muscle, liver and kidney of p53R2 knockout
mice [109]. Thus, proper maintenance of mtDNA relies on the expres-
sion of p53R2. Although some neurological conditions are reported in
patients with p53R2mutations, the effects of p53R2 deﬁciency onmito-
chondria in neural tissue have not been examined [109]. Nonetheless,
p53R2 is probably the only small subunit of ribonucleotide reductase
available in post-mitotic cells including neurons because the other
small subunit, R2, but not p53R2, is a degradation target for the
APC/C-Cdh1 E3 ubiquitin ligase [110], which is highly expressed in
neurons [111]. Although p53 inducibilty of p53R2 in neurons has not
yet been demonstrated, it would be worthwhile to determine if p53-
induced p53R2 expression can be used to protect mitochondrial func-
tion in neurons under conditions of aging and neurodegeneration. p53
also interacts with an F1F0 ATP synthase subunit to promote the assem-
bly of the ATP synthase complex, at least partially explaining how basal
levels of p53 in themitochondrialmatrix can increase oxygen consump-
tion and decrease mitochondrial superoxide production [112]. Collec-
tively, these studies indicate that, under physiological, mildly-stressed
conditions, constitutively expressed p53 can protect the mitochondrial
genome and supportmitochondrial biogenesis and function. In contrast,
as described above, accumulation of excess p53 in the mitochondrial
matrix in response to noxious levels of oxidative stress can trigger
opening of the permeability transition pore leading to programmed
necrotic cell death [51].
PGC-1α (peroxisome-proliferator-activated receptor gamma co-
activator-1α) is a co-transcriptional regulator that induces mitochon-
drial biogenesis by activating a host of different transcription factors in-
volved in the regulation of energy metabolism [113–115]. In p53
knockout mice mitochondrial content and the levels of PGC-1α in skel-
etal muscle tissue are reduced compared to wild-type tissue [116], and
reduced mtDNA content is associated with p53 deﬁciency in other
studies [98,103,105,106]. However, a recent study on mitochondrial
dysfunction stemming from telomere damage demonstrates that telo-
mere damage-induced p53 transcriptionally suppresses the expression
of PGC-1α (and PGC-1β) and, consequently, of PGC-1α transcriptional
targets including TFAM in different tissues of mice [117]. Changes in
the engagement of inducible/repressive p53-binding sites in the PGC-
1α promoter are conﬁrmed to be consistent with the suppressed
expression of PGC-1α [117]. This repressive regulation of PGC-1α ex-
pression by p53 is also demonstrable in p53-null ﬁbroblasts upon
adenovirus-mediated p53 overexpression, independently of telomere
damage [117]. Interestingly, a more recent study conversely demon-
strates that p53 can transcriptionally induce PGC-1α expression upon
GSH depletion in a nitric oxide-dependent manner in various human
cell types including SH-SY5Y cells and in mouse brain [118]. The dis-
crepancy between the two studies reﬂects whether p53 preferentially
binds to the positive or negative response elements in the PGC-1α pro-
moter. The negative response elements are predominantly occupied by
p53 in the telomere-damaged cells [117] and also in the non-GSH-
depleted control cells/tissues [118], but the positive response element
is predominantly occupied by p53 induced in response toGSHdepletion
[118]. Inhibition of nitric oxide synthase abolishes PGC-1α induction in
response to GSH depletion, suggesting that nitroxidative stress caused
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actually be a strictly nitric oxide-speciﬁc event because H2O2-
mediated oxidative stress results in p53-mediated PGC-1α downregu-
lation [119]. Also, the levels of p53 induced under these conditions
may be an important determinant of outcome with high (pro-death)
levels of p53 suppressing and low (pro-survival) levels of p53 inducing
PGC-1α expression. In these studies PGC-1α downregulation is pro-
death [117,119]while its upregulation is pro-survival [118], as expected
from the purported function of PGC-1α. Since p53-mediated PGC-1α
upregulation is demonstrable in dopaminergic SH-SY5Y neuroblastoma
cells and mouse brain [118], the PGC-1α gene in neurons may be posi-
tively regulated by p53 under certain conditions, if not as a default, and
thus activation of the p53-PGC-1α pathway may be neuroprotective. A
neuroprotective role for PGC-1α has been demonstrated for various
neurodegenerative conditions in vivo and in vitro [113,115].
Interestingly, PGC-1α, in turn, can regulate p53's transcriptional ac-
tivity by binding to p53 and modulating its transactivation preference
toward pro-cell cycle arrest and pro-metabolic target genes under con-
ditions of metabolic stress by blocking p53 acetylation at Lys120, which
is necessary for pro-apoptotic activation of p53 [120]. As this feedback
mechanism is also observed in SH-SY5Y neuroblastoma cells among
other cell types [120], the mechanism may also be intact in neurons
and contribute, at least in part, to the neuroprotective (anti-apoptotic)
effects of PGC-1α as revealed in overexpression and knockout studies
[113,115]. PGC-1α also directly resides in mitochondria and forms
complexes with TFAM and SIRT1 to associate with the D-loop region of
mtDNA [121], where it may also interact with p53 recruited to mtDNA
(see above). Interestingly, PGC-1α is more abundant (when normalized
against total protein) in mitochondria than in the nucleus in different
tissues including the brain [121], suggesting that PGC-1αmay contribute
to mitochondrial biogenesis as a transcriptional co-activator and/or via
protein–protein interactions within mitochondria.
4.3. p53 and metabolism (Fig. 2B)
Accumulating evidence indicates that p53 also plays an important role
in cellular metabolism by directly regulating glucose metabolism and
oxidative phosphorylation [122,123]. p53 decreases the expression of
pyruvate dehydrogenase kinase isoenzyme-2 (Pdk2) by transcriptional
repression [124], which facilitates the ﬂux of pyruvate to acetyl-CoA
rather than to lactate. In addition, p53 directly transactivates phosphate-
activated mitochondrial glutaminase (GLS2) [125,126], which promotes
a glutamine to glutamate conversion leading to enhanced generation of
α-ketoglutarate, a key TCA cycle intermediate. p53 also contributes to
maintenance of the mitochondrial oxidative phosphorylation machinery
by transcriptionally activating cytochrome c oxidase (COX) I subunit
(COX1/MT-COI) [127] and “synthesis of cytochrome c oxidase 2” (SCO2)
[128], which is required for the assembly of the COX II subunit into the
COX complex (complex IV), while post-transcriptionally maintaining
COX II subunit expression [129]. In addition, p53 transcriptionally induces
the expression of AIF [10],whichpromotes the proper assembly and func-
tion of respiratory complex I [130] separately from its apoptosis-related
function. Collectively, these p53 actions promote mitochondrial metabo-
lism and oxidative phosphorylation with a natural consequence of
increased production of reactive oxygen species (ROS). To counteract
this oxidative stress, p53 simultaneously upregulates anti-oxidant activity
through metabolic processes. p53-Mediated transcriptional activation of
GLS2 [125,126] and aldehyde dehydrogenase 4 (ALDH4) [131] helps to
maintain elevated levels of reduced glutathione (GSH) by supplying its
constituent, glutamic acid, from glutamine and proline, respectively, for
glutathione synthesis, thereby reducing ROS levels and conferring resis-
tance to oxidative stress. Perhaps more importantly, p53 regulates the
use of the pentose phosphate pathway (PPP) by transcriptionally induc-
ing “TP53-induced glycolysis and apoptosis regulator” (TIGAR) [132].
TIGAR possesses a fructose-2,6-bisphosphatase activity and shuttles glu-
cose to the PPP while suppressing glycolysis. The PPP is a key metabolicpathway supplyingNADPH required for regeneration of reduced glutathi-
one (GSH). However, there is another layer of regulation imposed on the
PPP as cytosolic p53 can inhibit glucose-6-phosphate dehydrogenase
(G6PDH) [133], which is the ﬁrst, rate-limiting enzyme of the PPP.
Therefore, the net effect of p53 on PPP activity may be determined by
the relative levels of nuclear versus cytoplasmic p53 and is clearly cell
and context dependent. In HCT116 colon cancer cells, p53's suppressive
effect on the PPP through G6PDH inhibition appears to dominate its
stimulatory effect through TIGAR induction as p53 deﬁciency results in
increased PPP ﬂux and higher NADPH levels [133].
It is not known if p53 regulates the PPP to any signiﬁcant extent in
neurons. Maintaining the integrity of this pathway is a prerequisite for
survival in neurons, and neurons possess a neuron-speciﬁc mechanism
to favor the PPP over glycolysis to cope with inherently high ROS
production. The enzyme 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase-3 (PFKFB3) acts as a key regulator of glycolysis by
synthesizing fructose-2,6-bisphosphate (the target of TIGAR) to
promote glycolysis. In neurons, the levels of PFKFB3 are kept low
through its continuous degradation by the highly expressed APC/C-
Cdh1 E3 ubiquitin ligase [111,134]. Because of this, the p53-TIGAR path-
waymay be redundant in neurons at least under resting conditions. The
PPP is probably not being obstructed by the p53-G6PDH interaction
under resting conditions because cytosolic p53 levels are likely to be
very low in healthy neurons. Therefore, p53-mediated regulation of
the PPPmay not be relevant in unstressed neurons. The intriguing ques-
tion then arises: how does this process changewhen p53 is upregulated
in neurons in response to stress? TIGAR induction may serve to ensure
the activity of the PPP in case stress-induced changes in intracellular sig-
naling favors the glycolytic pathway over the PPP, which may be detri-
mental to neuronal viability as suggested by the ﬁnding that inhibition
of the PPP can exacerbate stress-induced neuronal cell death [134]. Con-
versely, inhibition of G6PDHmayhelp dampen the excessive generation
of reduced glutathione (GSH) to enable mitophagy/autophagy which is
known to be activated by p53 (see above). Elevated TIGAR activity,
which favors the PPP, is known tomitigatemitophagy [78,135]. A partial
answermay come from the observation that, during glutamate-induced
apoptosis in cortical neurons, which is at least partially dependent on
p53 [136], PFKFB3 escapes degradation and its cytoplasmic accumula-
tion promotes glycolysis. This results in oxidative stress and cell death
that can be blocked by directly promoting the PPP via overexpression
of G6PDH [137], a PPP enzyme that is inhibited by p53 via direct inter-
action [133]. Therefore, in the context of excitotoxic stress, increased
PPP activity is clearly neuroprotective. Although upregulated p53 can
work both protectively through TIGAR induction and adversely by
inhibiting G6PDH, the outcome would heavily rely on the levels of nu-
clear vs. cytosolic p53 and it would be beneﬁcial if p53 could be
contained in the nucleus. Despite having been extensively discussed in
the context of the Warburg effect and tumor suppression [122,123],
thesemetabolic effects of p53 havenot been addressed for neuroprotec-
tion or neurodegeneration. A recent study implicates TIGAR expression
in Alzheimer's disease by showing that TIGAR protein expression is
lower with increasing severity of dementia, raising the possibility that
reduced TIGAR expression equates to a progressive loss of protection
against oxidative stress [138].
4.4. p53 and redox homeostasis (Fig. 2B)
Mitochondria are the major source of ROS production both in health
and death of a cell. ROS production is countered by the scavenging
actions of anti-oxidants. Physiological levels of ROS are important as
signaling molecules affecting cellular processes through modiﬁcation of
the activity of kinases and transcription factors including p53 [139]. Con-
versely, excess levels of ROS can provoke irreparable oxidative damage
and trigger cell death. p53 inﬂuences both the production and scavenging
of ROS by directly inducing and suppressing the expression of anti- and
pro-oxidant proteins, thereby maintaining redox homeostasis on one
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balance toward cell death.
As mentioned above, the anti-oxidant function of p53 is partly
mediated through the induction of ALDH4 [131], GLS2 [125,126] and
TIGAR [132], facilitating the synthesis of glutathione and the production
of NADPHwhich collectively increase the supply of reduced glutathione
(GSH). The remainder is accomplished through transcriptional induc-
tion of antioxidant proteins, sestrins (peroxiredoxin reductase) [140]
and glutathione peroxidase 1 (GPX1) [141]. p53-Inducible TP53INP1
also shows anti-oxidant activity, but the exactmechanism for this activ-
ity remains unknown [142]. Most notable among the other anti-oxidant
proteins, including those mentioned above, is another p53-regulated
anti-oxidant protein, manganese superoxide dismutase (MnSOD/
SOD2). Residing in the mitochondrial matrix, MnSOD protects mito-
chondria from oxidative damage by converting superoxide radicals to
H2O2, which are subsequently detoxiﬁed by peroxidases such as
mitochondrially localized GPX1 [143] and mitochondrial glutathione
[144]. Thus, intra-mitochondrial ROS detoxiﬁcation signiﬁcantly relies
on p53 target anti-oxidant proteins. Unlike other p53-inducible anti-
oxidant proteins, however, MnSOD expression is regulated by p53 in
both inductive and repressive ways although most studies report a re-
pressive action of p53 [145,146]. This may be explained by the observa-
tion that, when p53 levels are low, NF-κB is induced and binds to an
enhancer promoting MnSOD expression, whereas p53 and SP1 are re-
cruited to the promoter overriding the enhancer activity and suppress-
ing MnSOD expression when p53 levels are increased [147]. As found
for other p53 target proteins, p53 can also affectMnSOD function via di-
rect protein–protein interactions. Upon apoptosis induction with a
tumor promoter (TPA) in JB6 skin epidermal cells p53 translocates
into mitochondria, preceding its nuclear translocation, and binds to
and inactivates MnSOD causing mitochondrial depolarization [50]. In
mouse skin, however, UV-induced p53 translocates into the mitochon-
drial matrix and forms a complex with MnSOD and mitochondrial
DNA polymerase (Polγ), an important enzyme formtDNA base excision
repair, enabling MnSOD-dependent protection of Polγ from nitration-
induced inactivation [148]. Thus, p53's effect on MnDOS activity
through direct interactions appears to be context-dependent.
Pro-oxidant proteins are also induced by p53. p53 transcriptionally
upregulates ROS-generating enzymes such as quinone oxidoreductase
(NQO1/PIG3) [149], proline oxidase (POX/PIG6) [149] and ferredoxin
reductase (FR/FDXR) [150]. While overexpression of NQO1 [149] and
FR [150] only sensitize cells to apoptosis, POX overexpression induces
apoptosis [151,152], which is inhibited by MnSOD [152]. p66Shc (p66
isoform of Src homology 2 domain-containing-transforming protein
C1) has also attracted attention as a molecule that can mediate p53-
promoted ROS production by mitochondria [146,153,154]. Consistent
with targeted mutation of the p66shc gene prolonging life span in
mice [155], p66Shc−/− animals and cells show reduced levels of intra-
cellular ROS and increased resistance to oxidative stress such as UV,
H2O2 or paraquat [155,156]. p66Shc is transcriptionally regulated by
p53 in endothelial cells [157] and is also stabilized by p53 post-
translationally in mouse embryo ﬁbroblasts [156]. p66Shc induces
apoptosis by locally producing H2O2 through oxidation of cytochrome
c and, as a result, causes cyclosporine A-inhibitable mitochondrial
permeability transition [156].
The regulation of redox status by p53 in neurons may differ from its
regulation in other cell types. p53 deﬁciency lowers intracellular ROS
levels in cultured cortical neurons and cortical tissue while it elevates
ROS levels in embryonic lung ﬁbroblasts and liver and lung tissues
[158]. In normal ﬁbroblast and carcinoma cell lines increased ROS levels
are observed in response to p53 knockdown aswell under non-stressed
conditions [159]. Similarly, p53 maintains low ROS levels in neural
progenitor cells to suppress premature neurogenesis, indicating that
the mode of p53-mediated redox regulation is not yet neuronal [160].
Consistent with these contrasting effects of p53 on ROS levels, the
expression of pro- and anti-oxidant genes is differentially regulated byp53 in neurons compared toﬁbroblasts. The overall effect of p53 is to re-
press expression of anti-oxidant genes including those that have been
demonstrated to be p53 inducible in non-neuronal cells [158]. Although
MnSOD transcript levels did not differ signiﬁcantly between p53+/+
and p53−/− embryonic cortical neurons [158], another study reveals
signiﬁcantly increased expression of the MnSOD protein in mitochon-
drial fractions from p53−/−mouse brain relative to wild-type with re-
duced oxidative/nitrosative damage seen in mitochondrial and nuclear
fractions from p53−/− brain [161]. These studies indicate that, in con-
trast to non-neuronal cells, constitutive p53 expression is pro-oxidant in
neurons and in the nervous system, suggesting its implication in aging
and neurodegenerative conditions [162]. Under conditions associated
with neurodegeneration, reduced expression ofMnSOD is observed in as-
sociation with p53 upregulation in models of Alzheimer's disease [163]
while p53-dependent sestrin 2 upregulation occurs under conditions of
Parkinson's disease [164]. p66Shc deﬁciency reduces axonal injury in a
mouse model of multiple sclerosis [165] and protects hippocampal neu-
rons against cell death induced by H2O2 or NO donor treatment [166].
p66Shc also mediates β-amyloid neurotoxicity [167] and is required for
successful ischemic preconditioning in mixed neuron/glia cultures [168].
5. p53 and mitochondrial dynamics (Fig. 2C)
Maintaining propermitochondrial length is essential for normalmito-
chondrial function in neurons and dysregulated mitochondrial dynamics
has been associated with neuropathological conditions [169–171]. Mito-
chondrial fusion and ﬁssion affect bioenergetic efﬁciency and both exces-
sive and impaired ﬁssion or fusion lead to mitochondrial dysfunction
[172–175]. Speciﬁcally, excessive mitochondrial ﬁssion or fragmentation
is associatedwith and often causally related to neuronal cell death caused
by a variety of experimental toxic stressors [176–179]. Also, the process of
ﬁssion is tightly coupled with and is a prerequisite for mitophagy
[71,180], while fusion is required for maintenance of mutation-free
mtDNA assuring respiratory competence [181]. Mitochondrial ﬁssion
and fusion are regulated by dynamin-related GTPases, and include
dynamin-related protein 1 (Drp1) for ﬁssion and mitofusins (Mfn1 and
Mfn2) and optic atrophy-1 (OPA1) for fusion [182].
Recent studies suggest that p53 has direct implications for the regu-
lation ofmitochondrial dynamics by altering the expression and activity
of some of these ﬁssion/fusion proteins. p53 transcriptionally induces
expression of Mfn2 in HepG2 hepatocellular carcinoma cells [183] and
Drp1 in cardiomyocytes undergoing apoptosis [184]. p53 can also in-
duce mitochondrial ﬁssion in HeLa cells by promoting Drp1 transloca-
tion to mitochondria through transcriptional suppression of miR-499
and the resulting upregulation of calcineurin [185], a knownDrp1 phos-
phatase and activator [186]. p53-Dependent regulation of ﬁssion/fusion
proteins in neurons is also observed for Drp1. A recent study implicates
p53-Drp1 binding as a causal event to increased mitochondrial frag-
mentation and pathology in Huntington's disease (HD) using immortal-
ized mutant huntingtin (mtHtt: HdhQ111) knock-in mouse striatal cell
lines, human HD-iPS cell-derived striatal neurons and R2/6 HD mice
[187]. In this model, the levels of Drp1, but not p53, regulate mitochon-
drial co-accumulation of Drp1 and p53 although it was not demonstrat-
ed if p53/Drp1 complexes, which may also include huntingtin, are
formed in the cytosol before mitochondrial translocation or on the
mitochondrial surface [187]. Functionally, p53 suppression effectively
mitigates disease-associatedmitochondrial fragmentation and dysfunc-
tion (ROS production, loss of membrane potential) and cell death. Since
there is no additional beneﬁt observed with simultaneous direct inhibi-
tion of Drp1 activity, theﬁndings suggest that themajority ofmitochon-
drial pathology due to Drp-1 hyperactivation is mediated by p53's
interaction with Drp1 [187]. Studies from our laboratory demonstrate
that treatment of cultured postnatal cortical neurons with the DNA-
damaging agent camptothecin (CPT) results in elongatedmitochondria,
in contrast to fragmented mitochondria observed upon staurosporine
and glutamate treatment [74]. This is due to p53-dependent, post-
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tin ligase parkin, and overexpression of Drp1 or parkin corrects mito-
chondrial morphology and blocks associated neuronal cell death [74].
In contrast, CPT induces mitochondrial fragmentation in ﬁbroblasts
[74], suggesting cell type-speciﬁc regulation of Drp1 by p53. All of
these effects of p53 on mitochondrial ﬁssion/fusion proteins should
also inﬂuence mitophagy as mitochondrial ﬁssion is a prerequisite for
this important process [71,180].
6. Summary
The diverse range of functions performed by p53, evenwhen consid-
ered in the narrow context of mitochondria-related events, is telling ev-
idence for themultifunctional nature of the protein originally identiﬁed
as a tumor suppressor. In addition to its function as a transcription factor
evidence supports a role for direct mitochondria-related and cytosolic
functions of p53 in non-neuronal cells. In neurons, the apoptosis/
necrosis-inducing action of p53 directly at mitochondrial membranes
is gradually being unraveled, but little is known about its expression
levels and actions in the cytosol and the mitochondrial matrix under
physiological and pathological levels of stress. The mitochondrial
proteome currently contains more than 1000 proteins in humans and
mice [188]. Interestingly, only about half of the proteins registered in
the mitochondrial proteome may be shared between different tissue
types [189], reﬂecting cell type-speciﬁc gene expression and protein
localization for mitochondrial proteins. Given such heterogeneity, it
comes as no surprise that neurons lack certain speciﬁc p53 functions
demonstrated for non-neuronal cells and in turn display some
neuron-speciﬁc ones. One notable example may be the overall pro-
oxidant activity of p53 in neurons and the brain, which imposes a
constitutive oxidative stress burden on the nervous system [162]. The
lack of compelling evidence for the participation of the PINK1/parkin
pathway in mitophagy in neurons [72] in conjunction with p53-
mediated downregulation of parkin expression [74] also suggests the
presence of neuron-speciﬁc regulatory pathways for mitophagy.
It is clear that p53 exerts both pro-survival and pro-death actions
through mitochondria-related pathways. This dichotomy in p53 action
is clearly a product of the context-dependent action of p53 dictated,
for instance, by its levels of expression and activity (chemical modiﬁca-
tions), its subcellular localization (nuclear vs. cytosolic/mitochondria,
transcriptional vs. non-transcriptional) and the availability of its
interacting partners. Although knowledge regarding each of these pa-
rameters is still very limited for neurons, both actions may be simulta-
neously but separately targetable for neurodegenerative conditions,
potentially yielding a more neuroprotective outcome.
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